TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9689393

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.09 mg kg‐1, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pipecuronium (0.08 mg kg‐1, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atracurium (0.6 mg kg‐1, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg kg‐1, n = 10)
Number of subjects: 40
Study: 7857439

Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 (PGE2) 0.5 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative management (expectant management for 24 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous oxytocin (if labor not established)
Number of subjects: 52
Study: 2678652

Group type: EXPERIMENTAL
Intervention: 400 mg tolfenamic acid
Number of subjects: 149

Group type: COMPARATOR
Intervention: 1 g paracetamol
Number of subjects: 149
Study: 4717848

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activated charcoal or cholestyramine
Number of subjects: 0
Study: 30779718

Group type: EXPERIMENTAL
Intervention: Patients enrolled from 2005 to 2010
Number of subjects: 5159

Group type: EXPERIMENTAL
Intervention: Patients enrolled after 2010
Number of subjects: 5159

Group type: COMPARATOR
Intervention: Crude mortality rate in 1996
Number of subjects: 5159

Group type: COMPARATOR
Intervention: Crude mortality rate in 2013
Number of subjects: 5159

Group type: EXPERIMENTAL
Intervention: Daily fluid balance, tidal volume, plateau pressure, positive end-expiratory pressure
Number of subjects: 5159
Study: 28057550

Group type: EXPERIMENTAL
Intervention: LBPT 225mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: LBPT 300mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: LBPT 400mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: LBPT 500mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: LBPT under fasting conditions
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 25925557

Group type: EXPERIMENTAL
Intervention: Affected eyes with CRVO
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Affected eyes with BRVO
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 83
Study: 23996292

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen in 4.4 g transfersome gel (IDEA-033)
Number of subjects: 555

Group type: COMPARATOR
Intervention: 4.4 g ketoprofen-free vehicle (TDT 064)
Number of subjects: 555
Study: 21756276

Group type: COMPARATOR
Intervention: Transrectal ultrasonography-guided systematic bioptic sampling
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasonography
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasonography with SonoVue™ contrast agent
Number of subjects: 300
Study: 19805753

Group type: EXPERIMENTAL
Intervention: Colonoscopic surveillance (n = 1543)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Discharged following colonoscopy (n = 183)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No polyps (n = 26,573)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lower-risk polyps removed at FS (n = 7401)
Number of subjects: 26
Study: 16995327

Group type: EXPERIMENTAL
Intervention: Valdecoxib (20 mg, o.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg, o.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Metoprolol (50 mg)
Number of subjects: 15
Study: 12752651

Group type: EXPERIMENTAL
Intervention: Herofill Soft-Core system
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Thermomechanical compaction
Number of subjects: 64
Study: 12734781

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 570

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Insulin glargine (overweight subgroup)
Number of subjects: 570

Group type: COMPARATOR
Intervention: NPH insulin (overweight subgroup)
Number of subjects: 570
Study: 9876706

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intermittent intramuscular injection of morphine
Number of subjects: 72
Study: 8779655

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and related micronutrients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene, vitamin C, and vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary advice or intervention
Number of subjects: 0
Study: 2171616

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 461072

Group type: EXPERIMENTAL
Intervention: Orientation recognition task with two stimuli
Number of subjects: 2
Study: 31004689

Group type: EXPERIMENTAL
Intervention: Balance training (exercised twice a week for 12 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Blind relaxation group (control)
Number of subjects: 14
Study: 29390298

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ketamine (Group K)
Number of subjects: 44
Study: 25586727

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (2 g or equivalent)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 249
Study: 24099859

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21678430

Group type: EXPERIMENTAL
Intervention: Alcohol word primes
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nonalcohol word primes
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Alcohol word primes with aggressive target
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Visual presentation of alcoholic beverage images
Number of subjects: 104

Group type: COMPARATOR
Intervention: Visual presentation of nonalcoholic beverage images
Number of subjects: 104
Study: 19549431

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg twice daily (CIC80 b.i.d.)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily (CIC160 q.d.)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Ciclesonide treatments (CIC80 b.i.d. and CIC160 q.d.)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 446
Study: 16428009

Group type: EXPERIMENTAL
Intervention: Revised easy-to-read immunization pamphlets
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard vaccine information sheets
Number of subjects: 37
Study: 14745855

Group type: EXPERIMENTAL
Intervention: Caregiver skill‐building interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information/support interventions
Number of subjects: 0
Study: 11348454

Group type: EXPERIMENTAL
Intervention: 0.025% all‐trans retinoic acid
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5% sodium lauryl sulfate (irritant control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control area (occluded)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long-term (192 wk) all‐trans retinoic acid treatment (n = 5)
Number of subjects: 8
Study: 9237602

Group type: EXPERIMENTAL
Intervention: Beta Blockers (BB)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 210
Study: 8431375

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 40
Study: 29946873

Group type: EXPERIMENTAL
Intervention: Hot compress with Chinese herbal salt packets (CHSP) applied for 5-10 min before catheterization
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Hot compress with Chinese herbal salt packets (CHSP)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (conventional catheterization and nursing care)
Number of subjects: 720
Study: 26911315

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polyunsaturated fatty acids (PUFA) lotion 12%
Number of subjects: 12
Study: 24841184

Group type: EXPERIMENTAL
Intervention: Told‐NIC
Number of subjects: 51

Group type: COMPARATOR
Intervention: Told‐DENIC
Number of subjects: 51
Study: 22305830

Group type: EXPERIMENTAL
Intervention: RLX030 (recombinant form of human relaxin 2) 30 μg/kg per day IV infusion for 48 hours
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: RLX030
Number of subjects: 1160
Study: 20132129

Group type: EXPERIMENTAL
Intervention: Octreotide infusion (30 ng (kg min)(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (sodium chloride infusion)
Number of subjects: 8
Study: 18222389

Group type: EXPERIMENTAL
Intervention: Septic mice
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 13
Study: 16163679

Group type: EXPERIMENTAL
Intervention: Life Support Preferences Questionnaire (LSPQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Hispanic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hispanic patients
Number of subjects: 0
Study: 12514144

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micro g x kg(‐1) infused intravenously over 20 min)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal saline (control, equal volume infused intravenously over 20 min)
Number of subjects: 59
Study: 10376163

Group type: EXPERIMENTAL
Intervention: Diary recording using palmtop computers for 10 consecutive weeks
Number of subjects: 56
Study: 9016423

Group type: EXPERIMENTAL
Intervention: Standardized sign-out card
Number of subjects: 0
Study: 1510006

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg diltiazem
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg diltiazem
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg diltiazem
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg diltiazem
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.15 to 0.45 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 87
Study: 6090367

Group type: EXPERIMENTAL
Intervention: MDF (6141 cGy, 69 fractions, 4 1/2 weeks, at 89 cGy every 4 hours 3 times daily)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: MDF plus MISO (1.25 gm/M2 three times weekly for the first 3 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: CF (5800 cGy, 30 fractions, 6 weeks)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: High dose MDF (7120 cGy, 80 fractions, 5 1/2 weeks, at 89 cGy per fraction every 4 hours 3 times daily)
Number of subjects: 128
Study: 31783804

Group type: EXPERIMENTAL
Intervention: Subjects < 50 years
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subjects ≥ 50 years
Number of subjects: 45
Study: 29517274

Group type: EXPERIMENTAL
Intervention: PowerScope
Number of subjects: 28

Group type: COMPARATOR
Intervention: Forsus
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both PowerScope and Forsus
Number of subjects: 28
Study: 27652585

Group type: EXPERIMENTAL
Intervention: Sham feeding with gum chewing (two pieces of xylitol flavored gum for 15 minutes, three times a day after extubation until oral nutrition was tolerated)
Number of subjects: 59
Study: 24964348

Group type: EXPERIMENTAL
Intervention: Setipiprant 1000 mg b.i.d. for 5 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21979440

Group type: EXPERIMENTAL
Intervention: 60 g glucose dose after an overnight fast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 g glucose dose after a 2-hour fast
Number of subjects: 0
Study: 19496710

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17311061

Group type: EXPERIMENTAL
Intervention: TPN with glutamine (0.3 g/kg/days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard TPN (control group)
Number of subjects: 40
Study: 15738301

Group type: COMPARATOR
Intervention: Hypoxia at rest
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normoxic exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hypoxic exercise
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity testing
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of hypoxic ventilatory response and lung function parameters
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic pressure measurements
Number of subjects: 37
Study: 12533272

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9842756

Group type: EXPERIMENTAL
Intervention: Visual modality (below eye level)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tactile modality (below eye level)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Visual and tactile modalities (above eye level)
Number of subjects: 12
Study: 7727100

Group type: EXPERIMENTAL
Intervention: Superior corneal incision
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Temporal corneal incision
Number of subjects: 39
Study: 2643904

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (THEO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inhaled bitolterol (BITOL)
Number of subjects: 26
Study: 1146718

Group type: EXPERIMENTAL
Intervention: Micronor (progestogen type oral contraceptive)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ortho‐Novum SQ (sequential type oral contraceptive)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control cycle (no oral contraceptives)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Micronor and Ortho‐Novum SQ
Number of subjects: 13
Study: 30324895

Group type: EXPERIMENTAL
Intervention: ART-experienced patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: ART-naïve patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of sTNFR1 and sTNFR2 levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Different ART combinations
Number of subjects: 40
Study: 31682574

Group type: EXPERIMENTAL
Intervention: Culturally safe eHealth research practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: DREAM-GLOBAL RCT
Number of subjects: 0
Study: 28032550

Group type: EXPERIMENTAL
Intervention: Optilene LP mesh (OLP group)
Number of subjects: 145

Group type: COMPARATOR
Intervention: self-gripping Parietex ProGrip mesh (PPG group)
Number of subjects: 145
Study: 25399314

Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-intensity exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 14
Study: 23816814

Group type: EXPERIMENTAL
Intervention: levocetirizine hydrochloride 5 mg (Xyzal®) administered on day 8 after placebo for 7 days (treatment B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: levocetirizine hydrochloride 5 mg (Xyzal®) administered for 8 days (treatment C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo administered for 8 days (treatment A)
Number of subjects: 50
Study: 21188411

Group type: EXPERIMENTAL
Intervention: Hyper‐caloric fat‐rich diet (HFD) for 6 weeks
Number of subjects: 7
Study: 19267954

Group type: EXPERIMENTAL
Intervention: HP meal with 0.6% MSG and 0.25% IMP-5
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HP meal with MSG only
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HP meal with no additives
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham-fed meal 2 (oral-stimulation)
Number of subjects: 22
Study: 17224218

Group type: EXPERIMENTAL
Intervention: MMR vaccine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMR vaccine in combination with varicella (MMR and V)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed MMR vaccination (42 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytokine responses to phytohaemagglutinin and tetanus toxoid
Number of subjects: 0
Study: 15169694

Group type: EXPERIMENTAL
Intervention: Risperidone (1‐6 mg/day)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 11401073

Group type: EXPERIMENTAL
Intervention: Animal farmers (cattle, pigs, poultry, sheep)
Number of subjects: 6156
Study: 9572210

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 2.5 mg + E1 sulfate 1.25 mg
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 5 mg + E1 sulfate 1.25 mg
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg + E1 sulfate 1.25 mg
Number of subjects: 568
Study: 7999348

Group type: EXPERIMENTAL
Intervention: Behavioral treatment of depression in dementia patients
Number of subjects: 0
Study: 2741997

Group type: EXPERIMENTAL
Intervention: Sensorimotor integrative treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Functional treatment
Number of subjects: 90
Study: 790561

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30101636

Group type: EXPERIMENTAL
Intervention: Methotrexate and intra-articular glucocorticoids
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment, biologics, and no treatment
Number of subjects: 120
Study: 29947443

Group type: EXPERIMENTAL
Intervention: Individual Meaning‐Centered Psychotherapy (IMCP)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Patients with UB
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: UB-related distress
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: UB themes
Number of subjects: 223
Study: 26580483

Group type: EXPERIMENTAL
Intervention: Foraminal enlargement (FE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional nonforaminal enlargement (NFE)
Number of subjects: 70
Study: 25246569

Group type: EXPERIMENTAL
Intervention: High-resolution fMRI during a task taxing mnemonic discrimination of object identity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-resolution fMRI during a task taxing mnemonic discrimination of spatial location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-resolution fMRI during a task taxing mnemonic discrimination
Number of subjects: 0
Study: 22211956

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg + Sildenafil 50 mg
Number of subjects: 100
Study: 20304413

Group type: EXPERIMENTAL
Intervention: High protein, low carbohydrate diet (20 g/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low fat diet (30% of calories)
Number of subjects: 46
Study: 17627237

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 84
Study: 16256868

Group type: EXPERIMENTAL
Intervention: TriActiv System (Kensey Nash Corp.)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control group (Guardwire System or Filterwire EX)
Number of subjects: 631
Study: 12821836

Group type: EXPERIMENTAL
Intervention: Generic sodium stibogluconate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitamaquine (WR6026)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AmBisome
Number of subjects: 0
Study: 10504890

Group type: EXPERIMENTAL
Intervention: Peg-hole assembly task (manual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual character identification task (visual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined manual and visual tasks
Number of subjects: 0
Study: 8758170

Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg.kg‐1 preceded by 40 mg of topical lignocaine spray
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol 2.5 mg.kg‐1 alone
Number of subjects: 90
Study: 2206072

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (2.5 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 chip (3.0 mg)
Number of subjects: 69
Study: 6791231

Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam
Number of subjects: 0
Study: 30816331

Group type: EXPERIMENTAL
Intervention: Augmented intensity post induction intensification (PII)
Number of subjects: 2057

Group type: COMPARATOR
Intervention: Standard strength post induction intensification (PII)
Number of subjects: 2057

Group type: EXPERIMENTAL
Intervention: Idarubicin/cyclophosphamide
Number of subjects: 2057

Group type: COMPARATOR
Intervention: Weekly doxorubicin
Number of subjects: 2057
Study: 28486551

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation (CRT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 267
Study: 26077176

Group type: EXPERIMENTAL
Intervention: Sapropterin (5 mg/kg/day increased to 10 mg/kg on day 8)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24717838

Group type: EXPERIMENTAL
Intervention: Brivaracetam single dose (2.5-100 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brivaracetam multiple dose (2.5-50 mg twice daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brivaracetam in homozygous extensive metabolizers (EM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brivaracetam in heterozygous EM
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brivaracetam in poor metabolizers (PM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brivaracetam in PM participants
Number of subjects: 80
Study: 22791079

Group type: EXPERIMENTAL
Intervention: Biotin (1 mg/day)
Number of subjects: 14
Study: 20643186

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17013636

Group type: EXPERIMENTAL
Intervention: Active tea treatment (n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 75